Current and future treatment options for esophageal cancer in the elderly

References

• Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598–5606.
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92(3):549–555.
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387.
   PubMed Web of Science ®Google Scholar
• Cavallin F, Scarpa M, Cagol M, et al. Esophageal cancer clinical presentation: trends in the last 3 decades in a large Italian series. Ann Surg. 2016;1. [Epub ahead of print]
   PubMedGoogle Scholar
• Rantanen T, Oksala N, Sand J. Adenocarcinoma of the oesophagus and oesophagogastric junction: analysis of incidence and risk factors. Anticancer Res. 2016;36(5):2323–2329.
   PubMed Web of Science ®Google Scholar
• Xie SH, Mattsson F, Lagergren J. Incidence trends in oesophageal cancer by histological type: an updated analysis in Sweden. Cancer Epidemiol. 2017;47:114–117.
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E. Squamous cell carcinoma and adenocarcinoma of the esophagus – differences in etiology, epidemiology and prevention. Chinese-German J Clin Oncol. 2004;3:201–207.
   Google Scholar
• Gekid EV. Atlas der Krebsinzidenz und –mortalität in Deutschland (GEKID-Atlas). Lübeck; 2016.
   Google Scholar
• Feller A, Fehr M, Bordoni A, et al. Trends in incidence of oesophageal and gastric cancer according to morphology and anatomical location, in Switzerland 1982-2011. Swiss Med Wkly. 2015;145:w14245.
   PubMed Web of Science ®Google Scholar
• Robert-Koch Institut. Bericht zum Krebsgeschehen in Deutschland. Berlin, 2016.
   Google Scholar
• Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–1187.
   PubMed Web of Science ®Google Scholar
• Schroder W, Bollschweiler E, Kossow C, et al. Preoperative risk analysis – a reliable predictor of postoperative outcome after transthoracic esophagectomy? Langenbeck’s Archives of Surgery /Deutsche Gesellschaft Fur Chirurgie. 2006;391(5):455–460.
   PubMed Web of Science ®Google Scholar
• Balducci L. Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients. J Gastrointestinal Oncology. 2015;6(1):75–78.
   PubMed Web of Science ®Google Scholar
• Theou O, Brothers TD, Pena FG, et al. Identifying common characteristics of frailty across seven scales. J Am Geriatr Soc. 2014;62(5):901–906.
   PubMed Web of Science ®Google Scholar
• Balducci L. Studying cancer treatment in the elderly patient population. Cancer Control. 2014;21(3):215–220.
   PubMed Web of Science ®Google Scholar
• Cijs TM, Verhoef C, Steyerberg EW, et al. Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg. 2010;90(3):900–907.
   PubMed Web of Science ®Google Scholar
• Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014;21(3):209–214.
   PubMed Web of Science ®Google Scholar
• Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49(2):191–198.
   PubMed Web of Science ®Google Scholar
• Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg. 2011;254(1):67–72.
   PubMed Web of Science ®Google Scholar
• Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–823.
   PubMed Web of Science ®Google Scholar
• Le Page PA, Velu PP, Penman ID, et al. Surgical and endoscopic management of high grade dysplasia and early oesophageal adenocarcinoma. Surgeon. 2016;14(6):315–321.
   PubMed Web of Science ®Google Scholar
• Peng C, Shen S, Xu G, et al. Efficacy and safety of endoscopic submucosal dissection for elderly patients with superficial squamous esophageal neoplasms. United European Gastroenterol J. 2016;4(2):242–249.
   PubMed Web of Science ®Google Scholar
• Cummings LC, Kou TD, Schluchter MD, et al. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. Gastrointest Endosc. 2016;84(2):232-+.
   PubMed Web of Science ®Google Scholar
• Hölscher AH, Bollschweiler E, Schroder W, et al., Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 2011;254(5):802–807. discussion 807-808.
   PubMed Web of Science ®Google Scholar
• Metzger R, Lorenz D, Gockel I, et al. pT2 adenocarcinoma of the esophagus: early or advanced cancer? Ann Thorac Surg. 2013;96(5):1840–1845.
   PubMed Web of Science ®Google Scholar
• Paulson EC, Ra J, Armstrong K, et al., Underuse of esophagectomy as treatment for resectable esophageal cancer. Arch Surg. 2008;143(12):1198–1203. discussion 1203.
   PubMedGoogle Scholar
• Markar SR, Karthikesalingam A, Thrumurthy S, et al. Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy. Dis Esophagus. 2013;26(3):250–262.
   PubMed Web of Science ®Google Scholar
• Zehetner J, Lipham JC, Ayazi S, et al. Esophagectomy for cancer in octogenarians. Dis Esophagus. 2010;23(8):666–669.
   PubMed Web of Science ®Google Scholar
• Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205(6):729–734.
   PubMed Web of Science ®Google Scholar
• Moskovitz AH, Rizk NP, Venkatraman E, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2006;82(6):2031–2036. discussion 2036.
   PubMed Web of Science ®Google Scholar
• Tapias LF, Muniappan A, Wright CD, et al. Short and long-term outcomes after esophagectomy for cancer in elderly patients. Ann Thorac Surg. 2013;95(5):1741–1748.
   PubMed Web of Science ®Google Scholar
• Mcloughlin JM, Lewis JM, Meredith KL. The impact of age on morbidity and mortality following esophagectomy for esophageal cancer. Cancer Control. 2013;20(2):144–150.
   PubMed Web of Science ®Google Scholar
• Woodard GA, Crockard JC, Clary-Macy C, et al. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016;114(7):838–847.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Miyata H, Ozawa S, et al. Comparison of short-term outcomes between open and minimally invasive esophagectomy for esophageal cancer using a nationwide database in Japan. Ann Surg Oncol. 2017.
   Web of Science ®Google Scholar
• Straatman J, Van Der Wielen N, Cuesta MA, et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann Surg. 2017;1. [Epub ahead of print]
   PubMedGoogle Scholar
• Biere SS, Van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–1892.
   PubMed Web of Science ®Google Scholar
• Li J, Shen Y, Tan L, et al. Is minimally invasive esophagectomy beneficial to elderly patients with esophageal cancer? Surg Endosc. 2015;29(4):925–930.
   PubMed Web of Science ®Google Scholar
• Tang J, Humes DJ, Gemmil E, et al. Reduction in length of stay for patients undergoing oesophageal and gastric resections with implementation of enhanced recovery packages. Ann R Coll Surg Engl. 2013;95(5):323–328.
   PubMed Web of Science ®Google Scholar
• Oakley B, Lamb C, Vohra R, et al. Achieving long term survival in oesophagectomy patients aged over 75. Ann Med Surg (Lond). 2016;9:15–21.
   PubMed Web of Science ®Google Scholar
• Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–692.
   PubMed Web of Science ®Google Scholar
• Van Hagen P, Hulshof MC, Van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.
   PubMed Web of Science ®Google Scholar
• Hölscher AH, Bollschweiler E, Bogoevski D, et al. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – a propensity score matched analysis. Eur J Cancer. 2014;50(17):2950–2957.
   PubMed Web of Science ®Google Scholar
• Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–1733.
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–5067.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–1721.
   PubMed Web of Science ®Google Scholar
• Alderson D, Langley RE, Nankivell M, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol. 2015;33(suppl):abstr 4002.
   Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–1984.
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–3725.
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Pauligk C, Homann N, et al. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108(3):519–526.
   PubMed Web of Science ®Google Scholar
• Homann N, Pauligk C, Luley K, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130(7):1706–1713.
   PubMed Web of Science ®Google Scholar
• Schulz C, Kullmann F, Kunzmann V, et al. NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137(3):678–685.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49(4):835–842.
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–1092.
   PubMed Web of Science ®Google Scholar
• Shapiro J, Van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.
   PubMed Web of Science ®Google Scholar
• Molena D, Stem M, Blackford AL, et al. Esophageal cancer treatment is underutilized among elderly patients in the USA. J Gastrointest Surg. 2017;21(1):126–136.
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–856.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–360.
   PubMed Web of Science ®Google Scholar
• Klevebro F, Alexandersson Von Dobeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–667.
   PubMed Web of Science ®Google Scholar
• Favi F, Bollschweiler E, Berlth F, et al. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J Surg Oncol. 2017. In press.
   Web of Science ®Google Scholar
• Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7(5):325–333.
   PubMed Web of Science ®Google Scholar
• Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–2317.
   PubMed Web of Science ®Google Scholar
• Semrau R, Herzog SL, Vallbohmer D, et al. Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft … [Et Al]. 2012;188(3):226–232.
   PubMed Web of Science ®Google Scholar
• Lin SH, Zhang N, Godby J, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016;122(6):917–928.
   PubMed Web of Science ®Google Scholar
• Deschamps C, Nichols FC 3rd, Cassivi SD, et al. Long-term function and quality of life after esophageal resection for cancer and Barrett’s. Surg Clin North Am. 2005;85(3):649–656, xi.
   PubMed Web of Science ®Google Scholar
• Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91(2):199–204.
   PubMed Web of Science ®Google Scholar
• Schneider P, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6):902–908.
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Holscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250(6):888–894.
   PubMed Web of Science ®Google Scholar
• Heneghan HM, Donohoe C, Elliot J, et al. Can CT-PET and endoscopic assessment post-neoadjuvant chemoradiotherapy predict residual disease in esophageal cancer? Ann Surg. 2016;264(5):831–838.
   PubMed Web of Science ®Google Scholar
• Kumagai K, Mariosa D, Tsai JA, et al. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. Dis Esophagus. 2016;29(7):734–739.
   PubMedGoogle Scholar
• Hagen PV, Heijl MV, Henegouwen MI, et al. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: a prospective cohort study. Dis Esophagus. 2017; 30(2):1–7.
   PubMedGoogle Scholar
• Schmidt T, Lordick F, Herrmann K, et al. Value of functional imaging by PET in esophageal cancer. J Natl Compr Canc Netw. 2015;13(2):239–247.
   PubMed Web of Science ®Google Scholar
• Brabender J, Metzger R, Vallbohmer D, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer. Surgery. 2012;151(2):306–312.
   PubMed Web of Science ®Google Scholar
• Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg. 2008;12(11):1815–1821.
   PubMed Web of Science ®Google Scholar
• Findlay JM, Middleton MR, Tomlinson I. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol. 2015;26(4):624–644.
   PubMed Web of Science ®Google Scholar
• Miyazono F, Metzger R, Warnecke-Eberz U, et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91(4):666–672.
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Hölscher AH, Herbold T, et al. Molecular markers for the prediction of minor response to neoadjuvant chemoradiation in esophageal cancer. Results of the prospective Cologne Esophageal Response Prediction (CERP) study. Ann Surg. 2016;264(5):839–846.
   PubMed Web of Science ®Google Scholar
• Park JC, Lee YC, Kim JH, et al. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009;99(7):395–401.
   PubMed Web of Science ®Google Scholar
• Mahmood MQ, Shukla SD, Dua K, et al. The role of epidermal growth factor receptor in the management of: gastrointestinal carcinomas – present status and future perspectives. Curr Pharm Des. 2017. [Epub ahead of print]
   PubMedGoogle Scholar